|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
EP3252079B8
(en)
|
2006-04-07 |
2020-09-09 |
Aerpio Therapeutics LLC |
Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
|
|
US8475785B2
(en)
|
2008-03-03 |
2013-07-02 |
The University Of Miami |
Allogeneic cancer cell-based immunotherapy
|
|
WO2010077634A1
(en)
|
2008-12-09 |
2010-07-08 |
Genentech, Inc. |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
CA2772613C
(en)
|
2009-09-03 |
2020-03-10 |
Schering Corporation |
Anti-gitr antibodies
|
|
US20130017199A1
(en)
*
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
IL300733B1
(en)
*
|
2010-03-05 |
2025-10-01 |
Univ Johns Hopkins |
Compositions and methods for antibodies and fusion proteins targeted for immune modulation
|
|
DK2663579T3
(en)
|
2011-01-14 |
2017-07-31 |
Univ California |
THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
|
|
CA2830349C
(en)
|
2011-03-17 |
2019-07-16 |
The University Of Birmingham |
Re-directed immunotherapy
|
|
WO2012130471A1
(en)
*
|
2011-04-01 |
2012-10-04 |
Universität Stuttgart |
Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
|
|
CN107090040A
(zh)
|
2011-05-27 |
2017-08-25 |
艾伯维生物技术有限公司 |
Dac hyp组合物和方法
|
|
AU2012323856B2
(en)
|
2011-10-13 |
2017-05-25 |
EyePoint Pharmaceuticals, Inc. |
Methods for treating Vascular Leak Syndrome and cancer
|
|
BR112014009526B8
(pt)
*
|
2011-10-17 |
2023-01-17 |
Herlev Hospital |
Composição de vacina compreendendo pd-l1, kit de partes compreendendo tal composição e uso dos mesmos para tratar ou prevenir câncer
|
|
EP2812702B1
(en)
*
|
2012-02-10 |
2019-04-17 |
Seattle Genetics, Inc. |
Diagnosis and management of CD30-expressing cancers
|
|
AU2013251310B2
(en)
|
2012-04-27 |
2018-02-15 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
EP4219536A3
(en)
*
|
2012-04-30 |
2023-08-23 |
Biocon Limited |
Targeted/immunomodulatory fusion proteins and methods for making same
|
|
BR112015012644A2
(pt)
*
|
2012-11-30 |
2017-12-19 |
Hoffmann La Roche |
método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
|
|
US9657082B2
(en)
|
2013-01-31 |
2017-05-23 |
Thomas Jefferson University |
PD-L1 and PD-L2-based fusion proteins and uses thereof
|
|
EP2951209A4
(en)
|
2013-01-31 |
2016-06-22 |
Univ Jefferson |
CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
|
|
WO2015116178A1
(en)
*
|
2014-01-31 |
2015-08-06 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector t cells
|
|
EP2951199A4
(en)
|
2013-01-31 |
2016-07-20 |
Univ Jefferson |
Fusion proteins for the modulation of regulatory and effector T cells
|
|
EP2953634B1
(en)
|
2013-02-07 |
2021-05-26 |
The General Hospital Corporation |
Methods for expansion or depletion of t-regulatory cells
|
|
PT2970512T
(pt)
|
2013-03-12 |
2019-01-17 |
Biocon Ltd |
Proteínas de fusão imunomoduladoras e métodos para produção das mesmas
|
|
BR112015022210A8
(pt)
*
|
2013-03-13 |
2018-01-23 |
Genentech Inc |
formulações de anticorpo
|
|
WO2014168715A1
(en)
*
|
2013-04-08 |
2014-10-16 |
R-Pharm Overseas, Inc. |
B7 ligands/cd20 inhibitor composition and use thereof
|
|
JP2016519108A
(ja)
|
2013-04-18 |
2016-06-30 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
インターロイキン−１０を疾病及び疾患の治療に用いる方法
|
|
CA2918795A1
(en)
|
2013-07-25 |
2015-01-29 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
|
CN105658672A
(zh)
*
|
2013-08-22 |
2016-06-08 |
阿塞勒隆制药公司 |
TGF-β受体II型变体及其用途
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
CN105848674A
(zh)
*
|
2013-11-11 |
2016-08-10 |
阿尔莫生物科技股份有限公司 |
将白细胞介素-10用于治疗疾病和病症的方法
|
|
US9737623B2
(en)
|
2013-12-11 |
2017-08-22 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
CN105979961B
(zh)
*
|
2014-02-05 |
2020-12-18 |
西达-赛奈医疗中心 |
用于治疗癌症和感染性疾病的方法和组合物
|
|
SG11201606577YA
(en)
*
|
2014-02-10 |
2016-09-29 |
Merck Patent Gmbh |
TARGETED TGFβ INHIBITION
|
|
EP3338800A1
(en)
*
|
2014-02-21 |
2018-06-27 |
IDAC Theranostics, Inc. |
Therapeutic agent for solid cancer
|
|
JP2017507950A
(ja)
|
2014-02-27 |
2017-03-23 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
|
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
|
US20150307620A1
(en)
*
|
2014-04-16 |
2015-10-29 |
University Of Connecticut |
Linked immunotherapeutic agonists that costimulate multiple pathways
|
|
US9896441B2
(en)
|
2014-05-05 |
2018-02-20 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
|
JP6523337B2
(ja)
|
2014-05-05 |
2019-05-29 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
|
|
CN103965364B
(zh)
*
|
2014-05-19 |
2016-06-08 |
亚飞（上海）生物医药科技有限公司 |
一种人源pdl2hsa系列融合蛋白及其制备与应用
|
|
WO2015178746A1
(ko)
*
|
2014-05-23 |
2015-11-26 |
주식회사 제넥신 |
Pd-l1 융합 단백질 및 이의 용도
|
|
SMT202100116T1
(it)
|
2014-05-28 |
2021-05-07 |
Agenus Inc |
Anticorpi anti-gitr e metodi di utilizzo degli stessi
|
|
DK3151921T3
(da)
|
2014-06-06 |
2019-12-02 |
Bristol Myers Squibb Co |
Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
|
|
ES2818800T3
(es)
|
2014-06-11 |
2021-04-14 |
Idac Theranostics Inc |
Método para reducir los efectos secundarios de un agente de control del punto de control inmunitario
|
|
DK3172227T3
(da)
*
|
2014-07-21 |
2019-12-02 |
Delinia Inc |
Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
|
|
WO2016014974A2
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
EP3482766B1
(en)
|
2014-08-11 |
2020-05-20 |
Delinia, Inc. |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
JP7072384B2
(ja)
|
2014-09-15 |
2022-05-20 |
ジェネンテック， インコーポレイテッド |
抗体製剤
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
CA2963718A1
(en)
|
2014-11-14 |
2016-05-19 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer
|
|
WO2016118577A1
(en)
*
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
IL303543A
(en)
|
2015-02-18 |
2023-08-01 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11186824B2
(en)
|
2015-03-11 |
2021-11-30 |
Cellectis |
Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
|
|
MX2017011644A
(es)
|
2015-03-13 |
2017-12-04 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
|
|
WO2016156291A1
(en)
|
2015-03-31 |
2016-10-06 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a trimeric tnf family ligand
|
|
EP3281010B1
(en)
|
2015-04-10 |
2020-12-30 |
The Regents of The University of California |
Methods of determining patient populations amenable to immunomodulatory treatment of cancer
|
|
EP3283508B1
(en)
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
CN113106053A
(zh)
|
2015-04-21 |
2021-07-13 |
恩立夫克治疗有限责任公司 |
治疗性汇集的血液凋亡细胞制剂与其用途
|
|
CN107636014B
(zh)
*
|
2015-05-04 |
2021-12-07 |
皮里斯制药有限公司 |
抗癌融合多肽
|
|
AU2016257997A1
(en)
|
2015-05-05 |
2017-11-09 |
Lycera Corporation |
Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
|
|
TWI716405B
(zh)
|
2015-05-07 |
2021-01-21 |
美商艾吉納斯公司 |
抗ox40抗體及其使用方法
|
|
ES2962885T3
(es)
|
2015-05-15 |
2024-03-21 |
Massachusetts Gen Hospital |
Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral
|
|
CN107743586B
(zh)
|
2015-06-03 |
2021-07-02 |
百时美施贵宝公司 |
用于癌症诊断的抗gitr抗体
|
|
AU2016276947A1
(en)
|
2015-06-11 |
2017-12-14 |
Lycera Corporation |
Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
|
|
EP3322732A2
(en)
|
2015-07-13 |
2018-05-23 |
Cytomx Therapeutics Inc. |
Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
|
|
CA2986705A1
(en)
|
2015-07-16 |
2017-01-19 |
Biokine Therapeutics Ltd. |
A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
|
|
HK1248115A1
(zh)
|
2015-07-16 |
2018-10-12 |
Bioxcel Therapeutics, Inc. |
一种使用免疫调节治疗癌症的新颖方法
|
|
WO2017019729A1
(en)
|
2015-07-27 |
2017-02-02 |
The General Hospital Corporation |
Antibody derivatives with conditionally enabled effector function
|
|
CN116327952A
(zh)
|
2015-08-04 |
2023-06-27 |
阿塞勒隆制药公司 |
用于治疗骨髓增生性病症的方法
|
|
EP3341012B1
(en)
|
2015-08-25 |
2025-07-30 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
EP3340999A4
(en)
|
2015-08-28 |
2019-06-12 |
The General Hospital Corporation |
AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES
|
|
EP3344660B1
(en)
*
|
2015-08-31 |
2025-03-05 |
National Research Council of Canada |
Tgf-beta-receptor ectodomain fusion molecules and uses thereof
|
|
AU2016322934A1
(en)
*
|
2015-09-14 |
2018-04-12 |
Compass Therapeutics Llc |
Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
CN116063566A
(zh)
|
2015-10-01 |
2023-05-05 |
热生物制品有限公司 |
作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
|
|
KR20180053674A
(ko)
|
2015-10-02 |
2018-05-23 |
에프. 호프만-라 로슈 아게 |
공자극 tnf 수용체에 특이적인 이중특이성 항체
|
|
PE20180773A1
(es)
|
2015-10-02 |
2018-05-07 |
Hoffmann La Roche |
Anticuerpos biespecificos para pd1 y tim3
|
|
US20170107510A1
(en)
*
|
2015-10-14 |
2017-04-20 |
Batu Biologics, Inc. |
Dna nanoparticle based checkpoint inhibitors
|
|
MX2018005348A
(es)
|
2015-10-30 |
2018-08-14 |
Aleta Biotherapeutics Inc |
Composiciones y metodos para transduccion de tumores.
|
|
CA3002674A1
(en)
|
2015-10-30 |
2017-05-04 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
WO2017087784A1
(en)
*
|
2015-11-18 |
2017-05-26 |
Duke University |
Tumor infiltrating lymphocytes for treatment of cancer
|
|
BR112018010172A2
(pt)
|
2015-11-19 |
2018-11-21 |
Bristol Myers Squibb Co |
anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
|
|
EP3383430A4
(en)
|
2015-12-02 |
2019-12-18 |
Agenus Inc. |
ANTIBODIES AND METHOD FOR USE THEREOF
|
|
MX2018007406A
(es)
|
2015-12-16 |
2018-08-15 |
Merck Sharp & Dohme |
Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
CN108496084B
(zh)
*
|
2016-01-25 |
2021-11-05 |
赛诺菲 |
通过测量血浆生物标记的水平预测疑似患有癌症的患者使用阿柏西普的治疗的结果的方法
|
|
WO2017134592A1
(en)
*
|
2016-02-03 |
2017-08-10 |
Biocon Limited |
Anti-cd20/immunomodulatory fusion proteins and methods for making same
|
|
EP3416661A4
(en)
|
2016-02-18 |
2020-03-04 |
Enlivex Therapeutics Ltd. |
COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
EP3231813A1
(en)
*
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
|
CN116715767A
(zh)
|
2016-05-13 |
2023-09-08 |
综合医院公司 |
拮抗性抗肿瘤坏死因子受体超家族抗体
|
|
US11352413B2
(en)
|
2016-05-17 |
2022-06-07 |
Albert Einstein College Of Medicine |
Engineered PD-1 variants
|
|
AU2017268469C1
(en)
*
|
2016-05-20 |
2025-01-02 |
President And Fellows Of Harvard College |
Gene therapy methods for age-related diseases and conditions
|
|
MA45123A
(fr)
|
2016-05-27 |
2019-04-10 |
Agenus Inc |
Anticorps anti-tim-3 et leurs méthodes d'utilisation
|
|
CN109641936B
(zh)
|
2016-06-21 |
2023-11-28 |
Io生物技术公司 |
用于癌症疫苗中的pdl1肽
|
|
IL263616B2
(en)
|
2016-07-07 |
2025-01-01 |
Univ Leland Stanford Junior |
Antibody-adjuvant conjugates
|
|
EP3519442A4
(en)
*
|
2016-09-27 |
2020-06-17 |
EpicentRx, Inc. |
Immunomodulatory fusion proteins
|
|
CA3037380A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
|
EP3532488A4
(en)
*
|
2016-10-14 |
2020-04-29 |
Emory University |
NANOPARTICLES HAVING MOLECULES THAT BIND OR BLOCK PD-L1 AND THEIR USES IN THE TREATMENT OF CANCER
|
|
US20200038509A1
(en)
*
|
2016-10-14 |
2020-02-06 |
Baylor College Of Medicine |
Radiofrequency field hyperthermia and solid tumor immunomodulation
|
|
CN110167957A
(zh)
|
2016-11-08 |
2019-08-23 |
德里尼亚公司 |
用于治疗自身免疫疾病的il-2变体
|
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
|
IL300095A
(en)
*
|
2016-11-23 |
2023-03-01 |
Translational Drug Dev Llc |
Benzamide and tumor necrosis factor receptor superfamily agonist compositions and uses thereof
|
|
US11230596B2
(en)
|
2016-11-30 |
2022-01-25 |
Mereo Biopharma 5, Inc. |
Methods for treatment of cancer comprising TIGIT-binding agents
|
|
RU2019120398A
(ru)
|
2016-12-03 |
2021-01-12 |
Джуно Терапьютикс, Инк. |
Способы определения дозировки cart-клеток
|
|
CN110249046A
(zh)
|
2016-12-05 |
2019-09-17 |
朱诺治疗学股份有限公司 |
用于过继细胞疗法的工程化细胞的产生
|
|
US11299530B2
(en)
|
2017-01-05 |
2022-04-12 |
Kahr Medical Ltd. |
SIRP alpha-CD70 fusion protein and methods of use thereof
|
|
HRP20220230T1
(hr)
|
2017-01-05 |
2022-04-29 |
Kahr Medical Ltd. |
Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
|
|
WO2018127916A1
(en)
*
|
2017-01-05 |
2018-07-12 |
Kahr Medical Ltd. |
A pd1-cd70 fusion protein and methods of use thereof
|
|
IL267861B2
(en)
*
|
2017-01-05 |
2025-02-01 |
Kahr Medical Ltd |
PD1-41BBL conjugated protein and methods of using the same
|
|
CA3048646A1
(en)
*
|
2017-01-07 |
2018-07-12 |
Merck Patent Gmbh |
Dosing regimens and dosage forms for targeted tgf-b inhibition
|
|
AR110755A1
(es)
|
2017-01-20 |
2019-05-02 |
Genzyme Corp |
Anticuerpos dirigidos a hueso
|
|
TW202506185A
(zh)
|
2017-01-20 |
2025-02-16 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
|
AU2018214979A1
(en)
*
|
2017-02-01 |
2019-08-15 |
Acceleron Pharma Inc. |
TGFβ and actrii antagonists for use in increasing immune activity
|
|
EP3577133A1
(en)
|
2017-02-06 |
2019-12-11 |
Orionis Biosciences NV |
Targeted chimeric proteins and uses thereof
|
|
CN110381974A
(zh)
|
2017-02-27 |
2019-10-25 |
沙塔克实验室有限公司 |
基于csf1r的嵌合蛋白
|
|
CN110234345A
(zh)
*
|
2017-02-27 |
2019-09-13 |
沙塔克实验室有限公司 |
制备和使用基于细胞外结构域的嵌合蛋白的方法
|
|
US11192933B2
(en)
|
2017-02-27 |
2021-12-07 |
Shattuck Labs, Inc. |
VSIG8-based chimeric proteins
|
|
EP3589663A4
(en)
|
2017-03-02 |
2020-10-21 |
National Research Council of Canada |
TGF-ß RECEPTOR ECTODOMAIN FUSION MOLECULES AND THEIR USES
|
|
US20200150125A1
(en)
|
2017-03-12 |
2020-05-14 |
Yeda Research And Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
EP3600378A4
(en)
*
|
2017-03-24 |
2020-12-23 |
Orpheus Bioscience Inc. |
PANTIDS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
|
|
CN107082812B
(zh)
*
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
PT3606946T
(pt)
*
|
2017-04-03 |
2022-10-17 |
Hoffmann La Roche |
Imunoconjugados de um anticorpo anti-pd-1 com uma il-2 mutante ou com il-15
|
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
|
AU2018256406A1
(en)
|
2017-04-19 |
2019-10-17 |
Marengo Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
US11643473B2
(en)
*
|
2017-04-24 |
2023-05-09 |
Alexion Pharmaceuticals, Inc. |
Antibody immune cell inhibitor fusion proteins
|
|
TW202402800A
(zh)
|
2017-05-01 |
2024-01-16 |
美商艾吉納斯公司 |
抗ｔｉｇｉｔ抗體類和使用彼等之方法
|
|
DK3628049T3
(da)
*
|
2017-05-04 |
2023-08-14 |
Acceleron Pharma Inc |
Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
|
|
US11274142B2
(en)
|
2017-05-12 |
2022-03-15 |
Jiangsu Hengrui Medicine Co., Ltd. |
Fusion protein containing TGF-β receptor and medicinal uses thereof
|
|
MY201573A
(en)
|
2017-05-12 |
2024-03-02 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
JP7274426B2
(ja)
|
2017-05-16 |
2023-05-16 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｇｉｔｒアゴニスト抗体での癌の処置
|
|
MX2019013648A
(es)
|
2017-05-19 |
2021-01-08 |
Wuxi Biologics Shanghai Co Ltd |
Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4).
|
|
WO2018213747A1
(en)
*
|
2017-05-19 |
2018-11-22 |
Merrimack Pharmaceuticals, Inc. |
4-1bb agonist and cd40 agonist bispecific molecules
|
|
US20200140547A1
(en)
*
|
2017-05-26 |
2020-05-07 |
The Johns Hopkins University |
Multifunctional antibody-ligand traps to modulate immune tolerance
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
EP3630838A1
(en)
|
2017-06-01 |
2020-04-08 |
CytomX Therapeutics, Inc. |
Activatable anti-pdl1 antibodies, and methods of use thereof
|
|
CN107857819A
(zh)
*
|
2017-07-03 |
2018-03-30 |
江苏西迪尔生物技术有限公司 |
多功能融合蛋白及其应用
|
|
CA3071376A1
(en)
|
2017-08-03 |
2019-02-07 |
Amgen Inc. |
Interleukin-21 muteins and methods of treatment
|
|
JP7290013B2
(ja)
|
2017-08-04 |
2023-06-13 |
ジェンマブ エー／エス |
Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用
|
|
CN107602705B
(zh)
*
|
2017-09-13 |
2018-08-31 |
北京鼎成肽源生物技术有限公司 |
一种基于蛋白互作用于检测细胞pd1表达情况的融合蛋白及其应用
|
|
IL273626B2
(en)
|
2017-09-27 |
2025-07-01 |
Epicentrx Inc |
Immunomodulatory fusion proteins
|
|
JP2020535809A
(ja)
*
|
2017-09-29 |
2020-12-10 |
ナントセル，インコーポレイテッド |
抗原タンパク質及びそのための方法
|
|
KR102813968B1
(ko)
|
2017-10-10 |
2025-05-29 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
|
IL321773A
(en)
|
2017-10-14 |
2025-08-01 |
Cytomx Therapeutics Inc |
Activatable antibodies and methods for preparing them
|
|
AU2018352984B2
(en)
|
2017-10-18 |
2024-02-01 |
Precigen, Inc. |
Polypeptide compositions comprising spacers
|
|
US20190241659A1
(en)
*
|
2017-11-09 |
2019-08-08 |
Medimmune, Llc |
Bispecific fusion polypeptides and methods of use thereof
|
|
WO2019109053A1
(en)
|
2017-12-01 |
2019-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
|
WO2019113123A1
(en)
*
|
2017-12-04 |
2019-06-13 |
Precithera, Inc. |
TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
|
|
JP7348899B2
(ja)
*
|
2017-12-08 |
2023-09-21 |
マレンゴ・セラピューティクス，インコーポレーテッド |
多重特異性分子及びその使用
|
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
AU2019207895A1
(en)
|
2018-01-12 |
2020-06-18 |
Amgen Inc. |
Anti-PD-1 antibodies and methods of treatment
|
|
CN110151309B
(zh)
*
|
2018-02-14 |
2022-02-15 |
上海美杰医疗科技有限公司 |
多模态消融治疗术前规划方法及其设备
|
|
AU2019231205A1
(en)
*
|
2018-03-06 |
2020-09-24 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
|
TWI823906B
(zh)
|
2018-03-09 |
2023-12-01 |
美商艾吉納斯公司 |
抗-cd73 抗體及其使用方法
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
TW202003011A
(zh)
*
|
2018-03-26 |
2020-01-16 |
美商艾爾特生物科技責任有限公司 |
抗ＰＤＬ１、ＩＬ－１５及ＴＧＦ－β受體組合分子
|
|
MX2020010913A
(es)
|
2018-04-17 |
2021-01-08 |
Celldex Therapeutics Inc |
Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
|
|
JP2021522793A
(ja)
*
|
2018-05-03 |
2021-09-02 |
アクセルロン ファーマ インコーポレイテッド |
ＴＧＦβスーパーファミリーリガンドの多特異性バインダーおよびその使用
|
|
EP3788067A4
(en)
|
2018-05-03 |
2022-01-19 |
Acceleron Pharma Inc. |
NOVEL BINDERS OF TGFBETA SUPERFAMILY LIGANDS AND THEIR USES
|
|
WO2019211489A1
(en)
*
|
2018-05-04 |
2019-11-07 |
Merck Patent Gmbh |
COMBINED INHIBITION OF PD-1/PD-L1, TGFβ AND DNA-PK FOR THE TREATMENT OF CANCER
|
|
JP7542441B2
(ja)
|
2018-05-11 |
2024-08-30 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
癌を治療するための方法及び組成物
|
|
EP3807308A4
(en)
*
|
2018-06-15 |
2022-03-16 |
Acceleron Pharma Inc. |
BI AND TRIFUNCTIONAL FUSION PROTEINS AND THEIR USES
|
|
KR20210025525A
(ko)
|
2018-06-22 |
2021-03-09 |
카이트 파마 인코포레이티드 |
키메라 막횡단 단백질 및 그의 용도
|
|
WO2020006516A1
(en)
*
|
2018-06-29 |
2020-01-02 |
Gensun Biopharma, Inc. |
Antitumor immune checkpoint regulator antagonists
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
US11535669B2
(en)
*
|
2018-07-09 |
2022-12-27 |
Precigen, Inc. |
Fusion constructs and methods of using thereof
|
|
SG11202013167UA
(en)
|
2018-07-11 |
2021-01-28 |
Kahr Medical Ltd |
SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
|
|
SG11202013170RA
(en)
|
2018-07-11 |
2021-01-28 |
Kahr Medical Ltd |
Pd1-4-1bbl variant fusion protein and methods of use thereof
|
|
US12084497B2
(en)
|
2018-08-08 |
2024-09-10 |
Orionis Biosciences, Inc. |
SIRP1α targeted chimeric proteins and uses thereof
|
|
WO2020047329A1
(en)
*
|
2018-08-29 |
2020-03-05 |
Shattuck Labs, Inc. |
Chimeric proteins comprising extracellular domains and uses thereof
|
|
US10780121B2
(en)
|
2018-08-29 |
2020-09-22 |
Shattuck Labs, Inc. |
FLT3L-based chimeric proteins
|
|
CN109053895B
(zh)
|
2018-08-30 |
2020-06-09 |
中山康方生物医药有限公司 |
抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
|
|
US10894824B2
(en)
|
2018-09-24 |
2021-01-19 |
Aerpio Pharmaceuticals, Inc. |
Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
|
|
CN113164777B
(zh)
|
2018-09-27 |
2024-12-13 |
马伦戈治疗公司 |
Csf1r/ccr2多特异性抗体
|
|
US20220034880A1
(en)
*
|
2018-10-01 |
2022-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
High specificity and sensitivity immunosorbent diagnostic assays with simultaneous resolution of multiple antibody isotypes
|
|
US12291570B2
(en)
|
2018-10-17 |
2025-05-06 |
Biolinerx Ltd. |
Treatment of metastatic pancreatic adenocarcinoma
|
|
US20210355187A1
(en)
*
|
2018-10-24 |
2021-11-18 |
Shire-Nps Pharmaceuticals, Inc. |
Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
|
|
AU2019372436A1
(en)
|
2018-11-01 |
2021-05-20 |
Merck Patent Gmbh |
Methods of administering anti-TIM-3 antibodies
|
|
JP2022505925A
(ja)
|
2018-11-01 |
2022-01-14 |
メルク パテント ゲーエムベーハー |
抗ｔｉｍ－３抗体
|
|
MX2021005018A
(es)
|
2018-11-09 |
2021-06-15 |
Jiangsu Hengrui Medicine Co |
Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma.
|
|
WO2020123477A1
(en)
*
|
2018-12-10 |
2020-06-18 |
Bioxcel Therapeutics, Inc. |
Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
|
|
BR112021012631A2
(pt)
|
2018-12-26 |
2021-12-14 |
Xilio Dev Inc |
Anticorpos anti-ctla4 e métodos de uso dos mesmos
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
EP3927747A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
AU2020241686A1
(en)
|
2019-03-15 |
2021-11-04 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting HER2
|
|
EP3946437B1
(en)
|
2019-03-29 |
2025-11-19 |
H. Lee Moffitt Cancer Center and Research Institute, Inc. |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
|
US20220249558A1
(en)
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
BR112021025735A2
(pt)
*
|
2019-06-21 |
2022-03-08 |
Kite Pharma Inc |
Receptores de tgf-ss e métodos de uso
|
|
EP4582442A3
(en)
|
2019-06-24 |
2025-10-29 |
Universität Stuttgart |
Tnfr2 agonists with improved stability
|
|
WO2020263312A1
(en)
*
|
2019-06-28 |
2020-12-30 |
Gensun Biopharma, Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
|
US20220267442A1
(en)
*
|
2019-07-18 |
2022-08-25 |
Memorial Sloan Kettering Cancer Center |
METHODS AND COMPOSITIONS FOR TARGETING TGF-ß SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY
|
|
EP4011918A4
(en)
*
|
2019-08-08 |
2023-08-23 |
ONO Pharmaceutical Co., Ltd. |
DUAL SPECIFIC PROTEIN
|
|
WO2021041886A1
(en)
*
|
2019-08-29 |
2021-03-04 |
Nantbio, Inc. |
Modified n-810 and methods therefor
|
|
EP4023679A4
(en)
*
|
2019-08-30 |
2023-10-04 |
Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group |
FUSION PROTEIN TARGETING PD-L1 AND TGF-BETA AND USE THEREOF
|
|
WO2021054789A1
(ko)
*
|
2019-09-18 |
2021-03-25 |
주식회사 에스엘바이젠 |
신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
|
|
CN110734498A
(zh)
*
|
2019-10-15 |
2020-01-31 |
上海科棋药业科技有限公司 |
一种用于解除免疫抑制的融合蛋白及其应用
|
|
JP7495489B2
(ja)
*
|
2019-10-21 |
2024-06-04 |
ナンチン リーズ バイオラブス カンパニー，リミティド |
ＰＤ－１およびＴＧＦβを標的化する組換えタンパク質
|
|
CN114728072A
(zh)
|
2019-10-23 |
2022-07-08 |
库尔生物制药有限公司 |
TGF-β多肽
|
|
WO2021093760A1
(zh)
*
|
2019-11-12 |
2021-05-20 |
江苏恒瑞医药股份有限公司 |
含有TGF-β受体的融合蛋白及其医药用途
|
|
TWI772984B
(zh)
*
|
2019-11-27 |
2022-08-01 |
大陸商上海岸邁生物科技有限公司 |
TGFβ/PD-L1雙特異性結合蛋白
|
|
CN115023270A
(zh)
|
2019-11-27 |
2022-09-06 |
迈斯特治疗公司 |
使用调节剂产生肿瘤反应性t细胞组合物的方法
|
|
CN113004414B
(zh)
*
|
2019-12-20 |
2022-09-06 |
广东菲鹏制药股份有限公司 |
抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物
|
|
CN113121699A
(zh)
*
|
2019-12-30 |
2021-07-16 |
国典(北京)医药科技有限公司 |
Pttrap1双特异性融合蛋白及其应用
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
US20230123454A1
(en)
*
|
2020-01-23 |
2023-04-20 |
Genexine, Inc. |
Fusion protein comprising pd-l1 protein and use thereof
|
|
US11912751B2
(en)
*
|
2020-01-31 |
2024-02-27 |
Globetek Science Foundation |
Bi-functional fusion proteins comprised of TGF-B and immune checkpoint domains
|
|
IL295990A
(en)
|
2020-02-27 |
2022-11-01 |
Myst Therapeutics Llc |
Methods for in vitro enrichment and expansion of tumor-reactive t cells and preparations related thereto
|
|
US20230287081A1
(en)
*
|
2020-04-16 |
2023-09-14 |
Nantong Yichen Biopharma. Co. Ltd. |
PD-1 mutant polypeptide and preparation and application thereof
|
|
KR20230028242A
(ko)
|
2020-04-24 |
2023-02-28 |
마렝고 테라퓨틱스, 인크. |
T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
|
|
KR20230003114A
(ko)
*
|
2020-04-28 |
2023-01-05 |
사이노셀테크 엘티디. |
TGFβR2 세포외 도메인 절단된 분자, TGFβR2 세포외 도메인 절단된 분자와 항-EGFR 항체의 융합 단백질, 및 융합 단백질의 항종양 용도
|
|
CN111690070A
(zh)
*
|
2020-05-13 |
2020-09-22 |
深圳市众循精准医学研究院 |
一种sPD-1-Fc-sTGFβRII融合蛋白及其应用
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
WO2022011256A1
(en)
*
|
2020-07-10 |
2022-01-13 |
Precigen, Inc. |
Fusion constructs and methods of using thereof
|
|
CA3190766A1
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
|
WO2022057061A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Suzhou Neologics Bioscience Co., Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
EP4232063A4
(en)
*
|
2020-10-23 |
2025-01-01 |
HAN, Hq |
BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR-ALPHA AND TRANSFORMING GROWTH FACTOR-BETA AND THEIR USES
|
|
JP2023548346A
(ja)
*
|
2020-11-11 |
2023-11-16 |
ハン，ハック |
アクチビン／ｔｇｆ－ベータおよびｒａｎｋｌの二機能性アンタゴニストならびにその使用
|
|
CN114539415B
(zh)
*
|
2020-11-24 |
2024-02-02 |
普米斯生物技术(珠海)有限公司 |
一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
|
|
US20240082394A1
(en)
*
|
2020-12-15 |
2024-03-14 |
Bicara Therapeutics Inc. |
Combination therapy for the treatment of cancer
|
|
CN116829580A
(zh)
*
|
2020-12-15 |
2023-09-29 |
比卡拉治疗股份有限公司 |
用于融合蛋白的药物制剂
|
|
CA3210687A1
(en)
|
2021-02-17 |
2022-08-25 |
Cura Therapeutics, Inc. |
Anti-pathogen interleukin-tgf-beta receptor fusion polypeptides
|
|
AR125753A1
(es)
|
2021-05-04 |
2023-08-09 |
Agenus Inc |
Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
|
|
AU2022291370A1
(en)
*
|
2021-06-07 |
2024-01-04 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for targeted delivery of therapeutic agents
|
|
EP4373499A4
(en)
*
|
2021-07-21 |
2025-04-23 |
Mayo Foundation for Medical Education and Research |
Promoting immune surveillance against cancer cells
|
|
JP2024534263A
(ja)
*
|
2021-08-27 |
2024-09-18 |
セラノティックス カンパニー リミテッド |
Ｂ７－Ｈ３及びＴＧＦβに特異的に結合する二重特異性分子、並びにその用途
|
|
CN118302439A
(zh)
*
|
2021-09-24 |
2024-07-05 |
生物系统株式会社 |
包含pd-1和il-21的融合蛋白二聚体及其用途
|
|
US20240425579A1
(en)
|
2021-10-11 |
2024-12-26 |
Y-Trap, Inc. |
Compositions and methods that inhibit il-23 signaling
|
|
TW202334223A
(zh)
*
|
2021-11-11 |
2023-09-01 |
美商再生元醫藥公司 |
Ｃｄ２０－ｐｄ１結合分子及其使用方法
|
|
EP4514834A1
(en)
*
|
2022-04-28 |
2025-03-05 |
Immatics US, Inc. |
Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
|
|
CA3260155A1
(en)
*
|
2022-06-29 |
2024-01-04 |
Cdres Pharma Llc |
Immunologically active polypeptide
|
|
WO2024215772A2
(en)
*
|
2023-04-11 |
2024-10-17 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
AU2024204722A1
(en)
*
|
2023-05-31 |
2024-12-19 |
Fbd Biologics Limited |
Cd47/pd-l1-targeting protein complex and methods of use thereof
|
|
CN116514913B
(zh)
*
|
2023-06-07 |
2025-03-21 |
澳门大学 |
具有抗肿瘤活性的tnfr2靶向肽及其应用
|
|
WO2025006456A2
(en)
*
|
2023-06-26 |
2025-01-02 |
Protect Biotech Incorporation |
Compositions and methods for treating cancer
|